Altium Capital Management LP grew its holdings in shares of Curis, Inc. (NASDAQ:CRIS) by 7.4% in the second quarter, HoldingsChannel.com reports. The fund owned 829,000 shares of the biotechnology company’s stock after purchasing an additional 56,991 shares during the period. Curis accounts for about 1.6% of Altium Capital Management LP’s investment portfolio, making the stock its 11th largest holding. Altium Capital Management LP’s holdings in Curis were worth $6,690,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. increased its stake in Curis by 48.1% in the 1st quarter. BlackRock Inc. now owns 1,507,381 shares of the biotechnology company’s stock worth $17,063,000 after purchasing an additional 489,766 shares during the period. UBS Group AG increased its position in Curis by 6,679.8% in the first quarter. UBS Group AG now owns 130,240 shares of the biotechnology company’s stock worth $1,475,000 after buying an additional 128,319 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in Curis during the first quarter valued at approximately $144,000. Ensign Peak Advisors Inc purchased a new stake in Curis during the first quarter valued at approximately $915,000. Finally, Geode Capital Management LLC increased its holdings in Curis by 52.9% during the 1st quarter. Geode Capital Management LLC now owns 666,356 shares of the biotechnology company’s stock worth $7,543,000 after purchasing an additional 230,543 shares during the period. Hedge funds and other institutional investors own 88.55% of the company’s stock.
Several equities research analysts have commented on CRIS shares. Raymond James started coverage on Curis in a research note on Wednesday. They set an “outperform” rating and a $15.00 price objective for the company. B. Riley reiterated a “buy” rating and set a $22.00 target price on shares of Curis in a research note on Wednesday, August 4th. TheStreet cut shares of Curis from a “c-” rating to a “d” rating in a report on Thursday, June 17th. Finally, Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research report on Tuesday, October 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $18.50.
Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Monday, August 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.33 million. Curis had a negative net margin of 334.50% and a negative return on equity of 40.73%. On average, analysts anticipate that Curis, Inc. will post -0.49 EPS for the current year.
Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
Recommended Story: What are economic reports?
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.